Chronic Lymphocytic Leukemia

Testing for prognosis and risk stratification

Our chronic lymphocytic leukemia (CLL) testing provides important prognostic determination and assists physicians when determining the appropriate risk stratification to make informed treatment decisions for patients. This testing also meets all requirements of the National Comprehensive Cancer Network (NCCN) and CLL-International Prognostic Index (CLL-IPI) guidelines.

As highlighted by the new CLL-IWG recommendations and updated CLL-IPI. The need for all-encompassing testing for CLL patients is of upmost importance.  MCL offers all testing recommended by the CLL-IWG in one laboratory which reduces the need for splitting of patient samples and provides a continuity of care.

Which test should I order?

IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL)

Our goals today are, first of all, to understand the use of prognostic markers in CLL patients; second, to highlight the importance of molecular analyses for IGHV and TP53 sequencing in CLL patients; third, to understand how IGHV mutation analysis provides prognostic information in CLL and can help inform clinicians about possible treatment decisions; and, finally, recognizing that TP53 mutations identified by sequencing studies are associated with poor outcomes, since those patients are more likely to be resistant to standard therapeutic regimens.

Learn more about how to order these evaluations at your institution.

Additional Resources

Consortium study of Dohner Hierarchical Classification of chronic lymphocytic leukemia reveals improved survival

Back in 2000, a German study guided by Hartmut Dohner, M.D., established the prognostic association of chromosome abnormalities identified by fluorescence in situ hybridization (FISH) analysis in patients with chronic lymphocytic leukemia (CLL).

Curtis Hanson, M.D., discusses prognostic markers for chronic lymphocytic leukemia

Curtis Hanson, M.D., discusses the importance of detecting immunoglobulin heavy-chain variable (IGHV) gene mutation when acquiring prognostic and potentially therapeutic information in chronic lymphocytic leukemia (CLL) patients in CAP TODAY